Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 5/100

Failure Rate

9.8%

5 terminated/withdrawn out of 51 trials

Success Rate

89.4%

+2.9% vs industry average

Late-Stage Pipeline

39%

20 trials in Phase 3/4

Results Transparency

98%

41 of 42 completed trials have results

Key Signals

2 recruiting41 with results

Enrollment Performance

Analytics

Phase 2

24(49.0%)

Phase 3

20(40.8%)

N/A

4(8.2%)

Phase 1

1(2.0%)

49Total

Phase 2(24)

Phase 3(20)

N/A(4)

Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (51)

Showing 20 of 51 trials

NCT03263559Phase 2Completed

Haploidentical Bone Marrow Transplantation in Sickle Cell Patients (BMTCTN1507)

Role: collaborator

NCT06615050Phase 3Recruiting

A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 2203)

Role: collaborator

NCT02918292Phase 2Completed

Optimizing Haploidentical Aplastic Anemia Transplantation (BMT CTN 1502)

Role: collaborator

NCT04975698Phase 2Completed

HIV Antigen-specific T-cells Targeting Conserved Epitopes (HST-NEETs) BMTCTN1903

Role: collaborator

NCT04965597Phase 2Completed

Treosulfan-Based Conditioning Regimen Before a Blood or Bone Marrow Transplant for the Treatment of Bone Marrow Failure Diseases (BMT CTN 1904)

Role: collaborator

NCT05032820Phase 2Completed

Upfront Chimeric Antigen Receptor T-Cell to Upgrade Response in Multiple Myeloma

Role: collaborator

NCT05600426Phase 3Active Not Recruiting

A Trial Comparing Unrelated Donor BMT With IST for Pediatric and Young Adult Patients With Severe Aplastic Anemia (TransIT, BMT CTN 2202)

Role: collaborator

NCT04047628Phase 3Recruiting

Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)

Role: collaborator

NCT03904134Not ApplicableCompleted

Clinical Transplant-Related Long-term Outcomes of Alternative Donor Allogeneic Transplantation (BMT CTN 1702)

Role: collaborator

NCT04167514Phase 3Completed

Treatment of GVHD in Hematopoietic Stem Cell Transplant (HSCT) Recipients Using AAT Plus Corticosteroids (CS) Compared With Corticosteroids Alone

Role: collaborator

NCT02766465Phase 2Completed

Bone Marrow Transplantation vs Standard of Care in Patients With Severe Sickle Cell Disease (BMT CTN 1503)

Role: collaborator

NCT05353647Phase 2Active Not Recruiting

A Gene Transfer Study Inducing Fetal Hemoglobin in Sickle Cell Disease (GRASP, BMT CTN 2001)

Role: collaborator

NCT02997202Phase 3Completed

A Trial of the FMS-like Tyrosine Kinase 3 (FLT3) Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients With FLT3/Internal Tandem Duplication (ITD) Acute Myeloid Leukemia (AML)

Role: collaborator

NCT04934670Phase 3Terminated

A Study to Compare T-Guard vs Ruxolitinib for Treatment of Steroid-Refractory Acute Graft-vs-Host Disease (BMT CTN 2002)

Role: collaborator

NCT02728102Phase 2Completed

Dendritic Cell/Myeloma Fusion Vaccine for Multiple Myeloma (BMT CTN 1401)

Role: collaborator

NCT03959241Phase 3Completed

TAC/MTX vs. TAC/MMF/PTCY for Prevention of Graft-versus-Host Disease and Microbiome and Immune Reconstitution Study (BMT CTN 1703/1801)

Role: collaborator

NCT03992352Completed

Composite Health Assessment Risk Model (CHARM) for Older Adults (BMT CTN 1704)